Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging
- PMID: 37218941
- PMCID: PMC10204428
- DOI: 10.3390/tomography9030081
Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging
Abstract
Preclinical imaging is a critical component in translational research with significant complexities in workflow and site differences in deployment. Importantly, the National Cancer Institute's (NCI) precision medicine initiative emphasizes the use of translational co-clinical oncology models to address the biological and molecular bases of cancer prevention and treatment. The use of oncology models, such as patient-derived tumor xenografts (PDX) and genetically engineered mouse models (GEMMs), has ushered in an era of co-clinical trials by which preclinical studies can inform clinical trials and protocols, thus bridging the translational divide in cancer research. Similarly, preclinical imaging fills a translational gap as an enabling technology for translational imaging research. Unlike clinical imaging, where equipment manufacturers strive to meet standards in practice at clinical sites, standards are neither fully developed nor implemented in preclinical imaging. This fundamentally limits the collection and reporting of metadata to qualify preclinical imaging studies, thereby hindering open science and impacting the reproducibility of co-clinical imaging research. To begin to address these issues, the NCI co-clinical imaging research program (CIRP) conducted a survey to identify metadata requirements for reproducible quantitative co-clinical imaging. The enclosed consensus-based report summarizes co-clinical imaging metadata information (CIMI) to support quantitative co-clinical imaging research with broad implications for capturing co-clinical data, enabling interoperability and data sharing, as well as potentially leading to updates to the preclinical Digital Imaging and Communications in Medicine (DICOM) standard.
Keywords: Digital Imaging and Communications in Medicine (DICOM); co-clinical imaging; metadata; open science; preclinical imaging; reproducibility; standardization.
Conflict of interest statement
M.T.L. is a founder of and limited partner in StemMed Ltd., and a manager in StemMed Holdings, LP, its general partner. He is also a founder of and equity stake holder in Tvardi Therapeutics Inc.
Figures
References
Publication types
MeSH terms
Grants and funding
- U24CA226110/CA/NCI NIH HHS/United States
- U24 CA264298/CA/NCI NIH HHS/United States
- U24CA231858/CA/NCI NIH HHS/United States
- U24 CA220245/CA/NCI NIH HHS/United States
- U24CA237683/CA/NCI NIH HHS/United States
- U24 CA220325/CA/NCI NIH HHS/United States
- U24 CA253377/CA/NCI NIH HHS/United States
- U24 CA264044/CA/NCI NIH HHS/United States
- S10 OD030403/OD/NIH HHS/United States
- P50 CA228944/CA/NCI NIH HHS/United States
- U24 CA209837/CA/NCI NIH HHS/United States
- U24 CA253531/CA/NCI NIH HHS/United States
- P30 CA091842/CA/NCI NIH HHS/United States
- U24 CA237683/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous